Nurix Therapeutics, Inc. Common stock
Here’s whether Nurix Therapeutics, Inc. Common stock (NRIX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.21% over 10 days); RSI 46 — healthy momentum range; strong 1-year return of +41.7%; 3-month momentum positive (+10.2%); rising volume confirms the move (2.02x 30d avg). Currently 24.7% off its 52-week high. Score: +8/7.
NRIX is in a confirmed uptrend, trading above both its 50-day ($16.43) and 200-day ($14.92) moving averages. An RSI of 45.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +41.7% compares to +22.9% for SPY (beat the market by 18.9%). The current 24.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.